The United States Supreme Court issued its decision in Impression Products, Inc. v. Lexmark International, Inc. on patent exhaustion reversing the en banc decision of the CAFC.
This case presents two questions about the scope of the patent exhaustion doctrine: First, whether a patentee that sells an item under an express restriction on the purchaser’s right to reuse or resell the product may enforce that restriction through an infringement lawsuit. And second, whether a patentee exhausts its patent rights by selling its product outside the United States, where American patent laws do not apply. We conclude that a patentee’s decision to sell a product exhausts all of its patent rights in that item, regardless of any restrictions the patentee purports to impose or the location of the sale.(link)
Continue reading Exhaustion
The United States Supreme Court issued its decision in TC Heartland LLC v. Kraft Foods Group Brands LLC stating that corporate ‘residence’ refers only to the state of incorporation. The patent venue statute, 28 U. S. C. §1400(b), provides that “[a]ny civil action for patent infringement may be brought in the judicial district where the defendant resides, or where the defendant has committed acts of infringement and has a regular and established place of business.” This decision will likely have a significant effect on the number of cases filed in Texas, which saw 37% of all patent cases in 2016.
Continue reading Venue
My recent article on the use of protective and confidentiality orders in the Federal Court is available on Slaw. This topic was one of the items discussed last week at the Federal Court town hall and was the subject of an order released last week which stated, “The open court principle is of crucial importance in a democratic society, … Confidentiality orders inherently compromise these fundamental principles and important rights.” Continue reading Protective Orders
Bill C-30, the CETA implementation legislation received royal assent today. The Bill includes amendments to the Patent Act, regarding supplementary protection for pharmaceutical products and altering patent linkage system, and to the Trade-mark Act regarding geographic indicators with grounds of opposition and certain exceptions for prior use, acquired rights and generic terms. Amendments are also proposed to a number of other acts. Implementation regulations are expected any day.
Continue reading CETA
Health Canada has opened consultation on proposed amendments to the Patented Medicines Regulations including introducing new regulation factors, updated comparator countries, a complaints-based system for some products, and identification of pricing information and third party information required. Continue reading PMPRB
After a kickoff at the Diversity Breakfast, CBA IP Day continued with the Federal Court’s Town Hall focused on the imminent overhaul to pharmaceutical litigation in Canada, including two years to trial, focused discovery, changes to costs regime and efficient trial management. Bill C-30, the CETA implementation legislation cleared the senate this afternoon. Continue reading CBA IP Day
Looking forward to catching up with friends and colleagues at the CBA IP Day and Judges’ Dinner in Ottawa – please say hi if you will be there too. The day begins with a Diversity Breakfast and a Town Hall with members of the Federal Court, followed by the CBA IP Professional Development program in the afternoon and concludes with the Judges’ Dinner.
The Federal Court issued a practice notice on trial management conferences and procedures. The guidelines identify issues to be determined at pre-trial conferences and trial management conferences as well as impose new deadlines for pre-trial steps.
Continue reading Trial Management